
Scan beyond Amgen and see how other specialists in immunology and cardiometabolic care are priced by reviewing our hand-picked 34 high quality undervalued stocks.
To own Amgen, you need to be comfortable with a story that leans on immunology and cardiometabolic drugs to balance erosion in older biologics and the uncertainty around obesity pipelines. According to AnimalDoctorKwon, an investor in the Simply Wall St Community, the key tension is between legacy product pressure and expectations on newer assets.
The short term catalyst now is whether Amgen can keep executing on its existing franchises while funding obesity and autoimmune programs under a high debt load. The recent dazodalibep and Repatha data support the operating story, although they do not remove manufacturing and policy risk tied to obesity expectations.
Among recent updates, the Phase 3 OASIZ 301 data for dazodalibep matters most for this immunology narrative. A potential first in class CD40L antagonist with positive systemic and symptom outcomes in Sjögren's disease gives Amgen another shot at specialty autoimmune revenue as older brands face pricing and volume pressure.
For catalysts, this readout speaks directly to what AnimalDoctorKwon flags as a structural issue. The thesis that macro obesity demand and regulatory vouchers could carry Amgen looks fragile if Prolia and Enbrel erosion continues. Executing on dazodalibep, alongside Repatha and other specialty launches, becomes a practical counterweight to that concern.
On those numbers, AnimalDoctorKwon frames a fair value of US$359.98 for Amgen, based on a model that assumes revenue grows 7.5% a year and the business eventually settles at a 21.0% profit margin once obesity and autoimmune bets fully feed through.
Uncover why Amgen's fair value indicates a 23% potential downside to its current price, which leaves little room for error.
The bearish analysts focus on capital intensity rather than obesity hype. Their story is that Amgen’s US$2.6b 2026 capex and exposure to US$100b of 340B discounts could squeeze earnings. Before this Sjögren’s result, the lowest forecasts had revenue roughly flat and profit dropping to US$9.0b by 2029. That is a much harsher script. Use this as a cue to compare multiple narratives and see which assumptions fit your own view.
Explore 5 other Amgen fair value estimates, including one that suggests as much as 23% downside from the current price!
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
Once you have a view on Amgen, it helps to zoom out and compare it with other opportunities that fit different risk and income profiles. The Simply Wall St Screener lets you do that quickly by filtering for traits that match how you like to invest.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com